Prevalence and predictors of erectile dysfunction among men in the diabetes prevention program outcomes study

Authors

Yooni A. Blair, University of Michigan Department of Urology, Ann Arbor, MI, United States of America. Electronic address: yooniy@med.umich.edu.
Lindsay Doherty, Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
Marinella Temprosa, Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
Rodica Pop-Busui, University of Michigan Division of Metabolism, Endocrinology and Diabetes, Ann Arbor, MI, United States of America.
Kishore M. Gadde, University of California Irvine, Department of Surgery, Orange, CA, United States of America.
Prachi Singh, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, United States of America.
Arthur H. Owora, Indiana University School of Public Health Department of Epidemiology and Biostatistics, Bloomington, IN, United States of America.
Hunter Wessells, University of Washington School of Medicine Department of Urology and Diabetes Research Center, Seattle, WA, United States of America.
Aruna V. Sarma, University of Michigan Department of Urology, Ann Arbor, MI, United States of America.

Document Type

Journal Article

Publication Date

2-1-2024

Journal

Journal of diabetes and its complications

Volume

38

Issue

2

DOI

10.1016/j.jdiacomp.2023.108669

Keywords

Diabetes; Erectile dysfunction; Prediabetes

Abstract

OBJECTIVE: To determine burden and identify correlates of erectile dysfunction (ED) among men with prediabetes (PreD) and type 2 diabetes (T2D) enrolled in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS: The 2017 DPPOS visit included administration of the International Index of Erectile Function. Of 648 male participants, 88 % (n = 568) completed the survey. Associations between sociodemographic, behavioral, clinical, and glycemic measures at time of ED assessment, and ED were examined using multivariable logistic regression models in men with PreD and T2D separately. RESULTS: Overall, 218 (38 %) men met ED criteria. Prevalence was similar in men with PreD (41 %) and T2D (37 %) (p = 0.4). In all men, age (p < 0.001) increased odds of ED. Among men with PreD, those assigned to intensive lifestyle intervention (ILS), but not metformin, had decreased odds of ED compared with the placebo group (OR = 0.35, 95 % CI = 0.13, 0.94). Non-Hispanic White race was associated with increased odds of ED compared with other races (OR = 4.3; 95 % CI = 1.92, 9.65). Among men with T2D, ED risk did not differ by DPP treatment assignment; however, individuals with metabolic syndrome defined by National Cholesterol Education Program criteria, had increased odds of ED (OR = 1.85, 95 % CI = 1.14, 3.01), as did individuals with depression (OR = 2.05; 95 % CI = 1.10, 3.79). CONCLUSIONS: ED is prevalent in men with PreD and T2D. Our finding of reduced odds of ED in men randomized to ILS and with PreD suggests a potential opportunity for risk mitigation in the prediabetes interval. In men who have progressed to T2D, metabolic factors appear to be associated with ED.

APA Citation

Blair, Yooni A.; Doherty, Lindsay; Temprosa, Marinella; Pop-Busui, Rodica; Gadde, Kishore M.; Singh, Prachi; Owora, Arthur H.; Wessells, Hunter; and Sarma, Aruna V., "Prevalence and predictors of erectile dysfunction among men in the diabetes prevention program outcomes study" (2024). GW Authored Works. Paper 4426.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/4426

Department

Biostatistics and Bioinformatics